Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Distinct Sets of Genetic Alterations in Melanoma

Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747

Prevalence of ras gene mutations in human colorectal cancers

Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860

Somatic Activation of KIT in Distinct Subtypes of Melanoma

Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616

BRAF and RAS mutations in human lung cancer and melanoma.

Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

Chi, Z., Li, S., Sheng, X., Si, L., Cui, C., Han, M., & Guo, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-85 · Cited by 386

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing

Edlundh-Rose, E., Egyha??zi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., & Lundeberg, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232300.22032.86 · Cited by 318

Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma

Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Houben, R., Becker, J. C., Kappel, A., Terheyden, P. A. M., Bröcker, E., Goetz, R., & Rapp, U. R. (2004) · Journal of Carcinogenesis · doi:10.1186/1477-3163-3-6 · Cited by 294

N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., Schrier, P. I., & Bos, J. L. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.7.3114 · Cited by 283

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8503 · Cited by 275

Toward a Molecular Classification of Melanoma

Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Kong, Y., Si, L., Zhu, Y., Xu, X., Corless, C. L., Flaherty, K. T., Li, L., Li, H., Sheng, X., Cui, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2346 · Cited by 251

BRAF and NRAS mutations in melanoma and melanocytic nevi

Poynter, J. N., Elder, J. T., Fullen, D. R., Nair, R. P., Soengas, M. S., Johnson, T. M., Redman, B., Thomas, N. E., & Gruber, S. B. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222600.73179.f3 · Cited by 245

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

Ellerhorst, J. A., Greene, V. R., Ekmekcioglu, S., Warneke, C. L., Johnson, M. M., Cooke, C. P., Wang, L.-E., Prieto, V. G., Gershenwald, J. E., Wei, Q., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2276 · Cited by 243

RAS Mutations in Human Melanoma: A Marker of Malignant Progression

Ball, N. J., Yohn, J. J., Morelli, J. G., Norris, D. A., Golitz, L. E., & Hoeffler, J. P. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371783 · Cited by 221

Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.

Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A. N., BUSAM, K. J., & Polsky, D. (2003) · PubMed · Cited by 212

Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update

Ishihara, K., Saida, T., Otsuka, F., Yamazaki, N., & The Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0751-1 · Cited by 212

Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas

Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1169-3 · Cited by 212

Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.

Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon‐Cardo, C., McNutt, N. S., Bressler, J., & Andreeff, M. (1989) · PubMed · Cited by 212

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

Bauer, J., Büttner, P., Murali, R., Okamoto, I., Kolaitis, N. A., Landi, M. T., Scolyer, R. A., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00837.x · Cited by 211

BRAF mutations in metastatic melanoma: a possible association with clinical outcome.

Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka‐Kemppinen, M., Pyrhönen, S. O., & Hemminki, K. (2003) · PubMed · Cited by 205

Distinct Clinical and Pathological Features Are Associated with the BRAFT1799A(V600E) Mutation in Primary Melanoma

Liu, W., Kelly, J. W., Trivett, M., Murray, W. K., Dowling, J. P., Wolfe, R., Mason, G., Magee, J., Angel, C., Dobrovic, A., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700632 · Cited by 188

Analysis of N- and K-Ras Mutations in the Distinctive Tumor Progression Phases of Melanoma

Stas, M., Degreef, H., Demunter, A., De Wolf-Peeters, C., & van den Oord, J. J. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01601.x · Cited by 176

Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.

van Elsas, A., Zerp, S. F., van der Flier, S., Krüse, K. M., Aarnoudse, C. A., Hayward, N. K., Ruiter, D. J., & Schrier, P. I. (1996) · Europe PMC (PubMed Central) · Cited by 160

N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin

Jiveskog, S., Ragnarsson-Olding, B., Platz, A., & Ringborg, U. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00376.x · Cited by 155

Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.

Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U. K., & Hansson, J. (2002) · PubMed · Cited by 144

BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival

Akslen, L. A., Angelini, S., Straume, O., Bachmann, I. M., Molven, A., Hemminki, K., & Kumar, R. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23788.x · Cited by 111

Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians.

Byrd-Miles, K., Toombs, E. L., & Peck, G. L. (2007) · PubMed · Cited by 106

Could BRAF Mutations in Melanocytic Lesions Arise from DNA Damage Induced by Ultraviolet Radiation?

Thomas, N. E., Berwick, M., & Cordeiro‐Stone, M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700458 · Cited by 91

The Association between MC1R Genotype and BRAF Mutation Status in Cutaneous Melanoma: Findings from an Australian Population

Hacker, E., Hayward, N. K., Dumenil, T. D., James, M. R., & Whiteman, D. C. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.182 · Cited by 88

Clinical significance of BRAF mutations in metastatic melanoma

Chang, D. Z., Panageas, K. S., Osman, I., Polsky, D., BUSAM, K. J., & Chapman, P. B. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-46 · Cited by 65

BRAF Exon 15 T1799A Mutation Is Common in Melanocytic Nevi, but Less Prevalent in Cutaneous Malignant Melanoma, in Chinese Han

Qi, R.-Q., He, L., Zheng, S. G., Hong, Y., Ma, L., Zhang, S., Zhao, L., Guo, X., Wang, Y., Yu, J.-Y., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.405 · Cited by 46

Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations

Jovanovic, B., Egyházi, S., Eskandarpour, M., Ghiorzo, P., Palmer, J. M., Bianchi‐Scarrà, G., Hayward, N. K., & Hansson, J. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.287 · Cited by 37

Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases

Kirschner, M., Helmke, B. M., Starz, H., Benner, A., Thome, M., & Deichmann, M. (2005) · Melanoma Research · doi:10.1097/00008390-200510000-00011 · Cited by 20

Ten-year Audit of Melanoma in a Central England Population*

Hardwicke, J., Brunt, A. M., Rylands, G., & Rayatt, S. S. (2011) · Acta Dermato Venereologica · doi:10.2340/00015555-1069 · Cited by 8

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00210 · Cited by 175

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival

Hugdahl, E., Kalvenes, M. B., Puntervoll, H. E., Ladstein, R. G., & Akslen, L. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.44 · Cited by 75

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100661 · Cited by 14